Cost|effectiveness of Multigene Testing for All Patients With Breast ...

Cost-effectiveness of Multigene Testing for All Patients With Breast ...

Unselected BRCA1/BRCA2/PALB2 testing at breast cancer diagnosis was extremely cost-effective compared with BRCA1/BRCA2 testing based on clinical criteria or ...

A Cost-effectiveness Analysis of Multigene Testing for All Patients ...

Conclusions and relevance: This study found unselected, high-risk multigene testing for all patients with BC to be extremely cost-effective ...

Cost-Effectiveness of Multigene Testing for Breast and Ovarian Cancer

Population-wide genetic testing was 100% cost-effective for all the simulations in probabilistic sensitivity analyses; it became cost- ...

Cost-Effectiveness of Population-Based Multigene Testing for Breast ...

In this economic analysis of population-based multigene testing, population-based testing was a more cost-effective strategy for the ...

Multigene Testing Offers Cost-Effectiveness, Broader Approach to ...

A large US study showed population-based multigene testing might be a cost-effective way to identify women at risk for breast and ovarian cancer.

Multigene Testing of Everyone Diagnosed With Breast Cancer ...

A study found testing all people diagnosed with breast cancer for mutations in three genes linked to a high risk of the disease (BRCA1, ...

66 Should we offer multi-gene testing to all patients with breast cancer

Conclusions Unselected multigene-testing for all BC patients is extremely cost-effective compared with family-history/clinical-criteria testing for UK and US ...

Cost-Effectiveness of Targeted Genetic Testing for Breast and ...

Compared with BRCA alone, (3) multigene testing in women without cancer had an ICER of $51 800/QALY (one study), while for (4) multigene-cascade screening the ...

A Cost-effectiveness Analysis of Multigene Testing for All Patients ...

genetic testing in women with breast cancer (BC) who fulfill recognized or established family history (FH) or clinical criteria. These criteria ...

Cost-effectiveness of Multigene Testing for All Patients With Breast ...

Interview with Ranjit Manchanda, MD, author of A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.

The Cost-Effectiveness of Multigene Panel Testing for Hereditary ...

Results. Intermediate health outcomes improved by testing with multigene panels. At a cost-effectiveness threshold of $77,000, a 7-gene panel ...

Multigene testing for all patients with breast cancer cost-effective ...

Multigene testing for all patients with breast cancer could be a cost-effective way to reduce disease burden compared with testing based ...

All Women with Breast Cancer Should Undergo Multigene Testing ...

BRCA1/BRCA2/PALB2 multigene testing for all patients detected with BC would cost between $61,618 and $65,661 per QALY in the United States ...

Should we offer multi-gene testing to all patients with breast cancer

Probabilistic sensitivity-analysis shows unselected multigene-testing remains cost-effective for 98% UK/77% US health-system simulations. One year's unselected ...

Multigene Testing in Breast Cancer: Cost-effectiveness Analysis

“Testing all patients with breast cancer at diagnosis can increase testing access and uptake and identify many more pathogenic variant ...

Multigene testing for all breast cancer patients cost-effective

(HealthDay)—Unselected, multigene testing for all patients with breast cancer would be cost-effective in the United Kingdom and the United ...

Cost-effectiveness analyses of population-based multi-gene testing ...

The probabilistic sensitivity analyses show that the probability that population-based multi-gene testing is cost-effective is 100% for all the simulations.

A Multigene Test Could Cost-Effectively Help Extend Life ...

In the base-case scenario for a cohort of 50-year-old women at elevated risk of breast cancer, the seven-gene test strategy cost $282 more per woman tested and ...

Cost-Effectiveness of Genetic Testing for All Women Diagnosed with ...

We found that offering unselected multigene testing to all BC patients in China is highly cost-effective compared with FH/clinical-criteria-based testing or no ...

A cost-effectiveness analysis of multigene testing for all patients with ...

This is well below UK and US cost-effectiveness thresholds. In probabilistic sensitivity analysis, unselected multigene testing remained cost-effective for 98% ...